After concluding that Pfizers Bivalent Bivalent Vaccine complied with all safety, quality, and efficacy requirements set forth by UK regulators, British health authorities today approved its use as a booster.
The revised booster vaccine, which targets two different kinds of the Corona virus, has been licenced for use on people 12 years of age and older, according to the British government website. Noting that after carefully examining the facts, the British Human Medicines Committee endorsed this choice.
The initial virus strain is targeted by half of the booster vaccination (15 g), while omicron BA is the target of the other half (15 g).
Data from a clinical trial that indicated a booster dose of a Pfizer and Biontec bivalent vaccination induces a strong immune response against both Omicron and the initial strain were used to make the decision to approve. Since there are now no new, significant safety concerns, it is typically moderate and self-curing.
Dr. John Raine, the chief executive of the Medicines and Healthcare products Regulatory Agency, said: “I am happy to tell that we now have a second vaccination certified for the UK Autumn Boost Programme.” The original coronavirus strain and bivalent immunizations help us face the problem of a constantly changing virus by protecting patients from coronavirus mutations.
A novel bivalent booster vaccine from Pfizer and Biontech has been given approval for use in Britain.
About Author
